Compare
20/20 Biolabs, Inc. vs NeoGenomics Inc vs UL Solutions Inc.
| Latest fiscal year | 20/20 Biolabs, Inc. AIDX | NeoGenomics Inc NEO | UL Solutions Inc. ULS |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.05M | $727.33M | $3.05B |
| Revenue growth (YoY) | +16.7% | +10.1% | +6.4% |
| Gross margin | 29.6% | 43.2% | 49.5% (computed) |
| Operating margin | -162.9% | -15.9% | 17.1% |
| Net margin | -182.8% | -14.9% | 10.6% |
| Net income | -$3.74M | -$108.03M | $325.00M |
| EPS (Diluted) | -$0.76 | n/a | $1.60 |
| Operating cash flow | -$1.92M | $5.23M | $600.00M |
| Free cash flow | n/a | -$21.78M | $403.00M |
| Cash & equivalents | $1.03M | $159.62M | $295.00M |
| Total assets | $4.14M | $1.36B | $2.92B |
| Total liabilities | $4.16M | $523.27M | $1.63B |
| Shareholders' equity | -$19.2K | $836.56M | $1.29B |
| Return on year-end equity | n/a | -12.9% | 25.1% |
| Shares outstanding | 5.44M | 128.15M | 201.03M |
Revenue, most recent five fiscal years
| Fiscal year | 20/20 Biolabs, Inc. | NeoGenomics Inc | UL Solutions Inc. |
|---|---|---|---|
| Latest | $2.05M Ended 2025-12-31 | $727.33M Ended 2025-12-31 | $3.05B Ended 2025-12-31 |
| 1 year earlier | $1.75M Ended 2024-12-31 | $660.57M Ended 2024-12-31 | $2.87B Ended 2024-12-31 |
| 2 years earlier | n/a | $591.64M Ended 2023-12-31 | $2.68B Ended 2023-12-31 |
| 3 years earlier | n/a | $509.73M Ended 2022-12-31 | $2.52B Ended 2022-12-31 |
| 4 years earlier | n/a | $484.33M Ended 2021-12-31 | n/a |